Idorsia Ltd (SWX:IDIA)
4.020
+0.090 (2.29%)
At close: Dec 19, 2025
Idorsia Revenue
Idorsia had revenue of 41.49M CHF in the quarter ending September 30, 2025, with 58.35% growth. This brings the company's revenue in the last twelve months to 232.51M, up 213.69% year-over-year. In the year 2024, Idorsia had annual revenue of 112.51M, down -26.17%.
Revenue (ttm)
232.51M
Revenue Growth
+213.69%
P/S Ratio
4.32
Revenue / Employee
357.71K
Employees
650
Market Cap
1.00B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 112.51M | -39.88M | -26.17% |
| Dec 31, 2023 | 152.39M | 55.28M | 56.93% |
| Dec 31, 2022 | 97.10M | 61.75M | 174.70% |
| Dec 31, 2021 | 35.35M | -36.41M | -50.74% |
| Dec 31, 2020 | 71.76M | 47.94M | 201.26% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Roche Holding AG | 63.49B |
| Novartis AG | 44.95B |
| Sandoz Group AG | 8.42B |
| Alcon | 8.12B |
| Lonza Group AG | 7.09B |
| Galenica AG | 4.03B |
| Sonova Holding AG | 3.85B |
| Galderma Group AG | 3.73B |
Idorsia News
- 10 days ago - Idorsia Highlights New PRECISION Study Analysis Showing Strong Results For Aprocitentan - Nasdaq
- 11 days ago - New Hypertension publication underscores aprocitentan's potential in managing hypertension patients with CKD - Benzinga
- 11 days ago - Idorsia's treatment for insomnia disorder wins the inaugural Prix Galien Bridges Award in the ‘Best Biotechnology & Pharmaceutical Product' category - GlobeNewsWire
- 5 weeks ago - Idorsia's aprocitentan improved key prognostic indicators in patients with difficult-to-control hypertension - Benzinga
- 5 weeks ago - Idorsia's aprocitentan improved key prognostic indicators in patients with difficult-to-control hypertension - GlobeNewsWire
- 6 weeks ago - Idorsia to present new aprocitentan insights at ASN Kidney Week & AHA Scientific Sessions - GlobeNewsWire
- 7 weeks ago - QUVIVIQ sales up >130% driving Idorsia toward profitability – 9M 2025 results - GlobeNewsWire
- 2 months ago - Idorsia successfully completes an upsized offering of shares – funding the company to overall profitability - GlobeNewsWire